US FDA approves Jazz Pharma's drug for rare brain tumor-January 2024-www.financetom.com

US FDA approves Jazz Pharma's drug for rare brain tumor

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Jazz Pharma's drug for rare brain tumor

Aug 6, 2025 11:57 AM

Aug 6 (Reuters) - The U.S. Food and Drug Administration

said on Wednesday that it has approved Jazz Pharmaceuticals' ( JAZZ )

drug to treat diffuse midline glioma, a rare and

aggressive tumor, in adults and children aged one year and

older.

Previous page： Toll Brothers Insider Sold Shares Worth $346,783, According to a Recent SEC Filing Next page： Toll Brothers Insider Sold Shares Worth $3,456,385, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Toll Brothers Insider Sold Shares Worth $346,783, According to a Recent SEC Filing

Sep 2, 2025

04:11 PM EDT, 09/02/2025 (MT Newswires) -- Wendell E. Pritchett, Director, on September 02, 2025, sold 2,500 shares in Toll Brothers ( TOL ) for $346,783. Following the Form 4 filing with the SEC, Pritchett has control over a total of 13,511 common shares of the company, with 13,511 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/794170/000079417025000070/xslF345X05/form4.xml ...

Toll Brothers Insider Sold Shares Worth $3,456,385, According to a Recent SEC Filing

Sep 2, 2025

04:09 PM EDT, 09/02/2025 (MT Newswires) -- Douglas C. Yearley Jr., Director, Chief Executive Officer, on August 29, 2025, sold 25,000 shares in Toll Brothers ( TOL ) for $3,456,385. Following the Form 4 filing with the SEC, Yearley has control over a total of 368,664 common shares of the company, with 286,117 shares held directly and 82,547 controlled indirectly....

Health-savings account manager HealthEquity Q2 revenue beats estimates

Sep 2, 2025

Overview * HealthEquity Inc ( HQY ) Q2 revenue grows 9%, beating analyst expectations, per LSEG data * Net income for Q2 misses analyst estimates, per LSEG data * Adjusted EBITDA rises 18%, exceeding expectations, per LSEG data Outlook * Company expects fiscal year revenue of $1.290 bln to $1.310 bln * HealthEquity ( HQY ) projects net income between...

Ryerson Holding Insider Sold Shares Worth $337,050, According to a Recent SEC Filing

Sep 2, 2025

04:11 PM EDT, 09/02/2025 (MT Newswires) -- Alagu Sundarrajan, Chief Information Officer, on August 28, 2025, sold 15,000 shares in Ryerson Holding ( RYI ) for $337,050. Following the Form 4 filing with the SEC, Sundarrajan has control over a total of 17,005 common shares of the company, with 17,005 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1481582/000184829225000002/xslF345X05/primary_doc.xml ...